✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Pyrrole-2-Carboxylate is an investigational drug.
There have been 6 clinical trials for Pyrrole-2-Carboxylate. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2020.
The most common disease conditions in clinical trials are Breast Neoplasms, Urolithiasis, and Urinary Calculi. The leading clinical trial sponsors are West China Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, and Assiut University.
There are six hundred and eighty US patents protecting this investigational drug and eight international patents.
Recent Clinical Trials for Pyrrole-2-Carboxylate
|Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer||West China Hospital||Phase 2|
|Effect of Rosuvastatin on the Clinical Features of Preeclampsia||Assiut University||Phase 2|
|Prophylactic Anticoagulation for Catheter-related Thrombosis||Second Affiliated Hospital, School of Medicine, Zhejiang University||Phase 4|
Top disease conditions for Pyrrole-2-Carboxylate
Top clinical trial sponsors for Pyrrole-2-Carboxylate
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Pyrrole-2-Carboxylate||See Plans and Pricing||Compounds useful for the treatment of metabolic disorders and synthesis of the same||North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC)||See Plans and Pricing|
|Pyrrole-2-Carboxylate||See Plans and Pricing||Compounds||CHIESI FARMACEUTICI S.P.A. (Parma, IT)||See Plans and Pricing|
|Pyrrole-2-Carboxylate||See Plans and Pricing||Tank-binding kinase inhibitor compounds||Gilead Sciences, Inc. (Foster City, CA)||See Plans and Pricing|
|Pyrrole-2-Carboxylate||See Plans and Pricing||Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders||Avoscience, LLC (Hayden, ID)||See Plans and Pricing|
|Pyrrole-2-Carboxylate||See Plans and Pricing||SHIP1 modulators and methods related thereto||Aquinox Pharmaceuticals (Canada) Inc. (Vancouver, CA)||See Plans and Pricing|
|Pyrrole-2-Carboxylate||See Plans and Pricing||Pyrazolone compounds having human neutrophil elastase inhibitory properties||Chiesi Farmaceutici S.p.A. (Parma, IT)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Pyrrole-2-Carboxylate||European Patent Office||EP3260297||2036-06-24||See Plans and Pricing|
|Pyrrole-2-Carboxylate||Japan||JP2018001759||2036-06-24||See Plans and Pricing|
|Pyrrole-2-Carboxylate||Japan||JP6921643||2036-06-24||See Plans and Pricing|
|Pyrrole-2-Carboxylate||World Intellectual Property Organization (WIPO)||WO2014165816||2033-04-05||See Plans and Pricing|
|Pyrrole-2-Carboxylate||Japan||JP2016215640||2035-05-18||See Plans and Pricing|
|Pyrrole-2-Carboxylate||Japan||JP6775998||2035-05-18||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|